<doc>
  <docmeta id="113hr4798ih">
    <bill congress="113" type="hr" number="4798" version="ih"/>
    <revision size="6877" annotations="0" status="complete" id="6" commit-time="2014-06-12T16:29:35Z" committer="mbohmer" doc="113hr4798ih/6.xml">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="HDF8B503AE23549A7B57F6BE43AE23AE8" public-private="public">
	<metadata>
<dublinCore>
<dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">113 HR 4798 IH: United States-Israel Alzheimer’s Disease Cooperation Act</dc:title>
<dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">U.S. House of Representatives</dc:publisher>
<dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2014-06-02</dc:date>
<dc:format xmlns:dc="http://purl.org/dc/elements/1.1/">text/xml</dc:format>
<dc:language xmlns:dc="http://purl.org/dc/elements/1.1/">EN</dc:language>
<dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/">Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>2d Session</session>
		<legis-num>H. R. 4798</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20140602">June 2, 2014</action-date>
			<action-desc>
        <sponsor name-id="I000057">Mr. Israel</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>
      </action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To authorize the Secretary of Health and Human Services to award grants for Alzheimer’s disease
			 research.</official-title>
	</form>
	<legis-body id="HDE9BD10BA4BA48AD91390E2BBA8FA0A8" style="OLC">
		<section id="H3CE6B625F4054A52A1386E47E6EBCAE3" section-type="section-one">
      <enum>1.</enum>
      <header>Short title</header>
      <text display-inline="no-display-inline">This Act may be cited as the <quote>
          <short-title>
            <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="United States-Israel Alzheimer’s Disease Cooperation Act" proposed="true">United States-Israel Alzheimer’s Disease Cooperation Act</cato:entity-ref>
          </short-title>
        </quote>.</text>
		</section>
    <section id="HD655D74B754842BE8CBD6F95424BA964">
      <enum>2.</enum>
      <header>Findings</header>
      <text display-inline="no-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref> finds the following:</text>
			<paragraph id="H63AF6C70A77E41E0A50F759AE8CF3A50">
        <enum>(1)</enum>
        <text>It is in the highest national interests of the United States to further research into Alzheimer’s
			 disease.</text>
			</paragraph>
      <paragraph id="HD64F519C85984CCE9945562EAA547B88">
        <enum>(2)</enum>
        <text>The State of Israel is a steadfast ally of the United States.</text>
			</paragraph>
      <paragraph id="H3BEA90707C574F27A2521249E4186792">
        <enum>(3)</enum>
        <text>The special relationship between the United States and Israel is manifested in a variety of
			 cooperative scientific research and development programs, such as—</text>
				<subparagraph id="HF76B8EC19F4048FA80B21F6272EC3FD7">
          <enum>(A)</enum>
          <text>the United States-Israel Binational Science Foundation;</text>
				</subparagraph>
        <subparagraph id="H0F8F41C9877848B0BFC4938AF19888D5">
          <enum>(B)</enum>
          <text>the United States-Israel Binational Industrial Research and Development Foundation; and</text>
				</subparagraph>
        <subparagraph id="H62E5BDC92FB5415A92E8F9E866C57A59">
          <enum>(C)</enum>
          <text>the United States-Israel Energy Cooperation Act.</text>
				</subparagraph>
      </paragraph>
      <paragraph id="HB9F47859F5F2466AA15028596B9D6D66">
        <enum>(4)</enum>
        <text>Those programs have made possible many scientific, technological, and commercial breakthroughs in
			 fields including the life sciences, medicine, bioengineering, agriculture,
			 biotechnology, communications, and energy development.</text>
			</paragraph>
      <paragraph id="HCEBD456C584745B48080ADD662973491">
        <enum>(5)</enum>
        <text>Israeli scientists are at the forefront of research and development in the field of Alzheimer’s
			 disease.</text>
			</paragraph>
      <paragraph id="HAF9B2675E2394CB39245979E7C299FA3">
        <enum>(6)</enum>
        <text>Enhanced cooperation between the United States and Israel for the purpose of research in
			 Alzheimer’s disease would be in the national interests of both countries.</text>
			</paragraph>
    </section>
    <section id="HA9980B8FF27542D8BAE44E3611C98623" section-type="subsequent-section">
      <enum>3.</enum>
      <header>Grants for Alzheimer’s disease research</header>
			<subsection id="HDDCD06463E9D434EB350E3DCCA906E99">
        <enum>(a)</enum>
        <header>Grant program</header>
				<paragraph id="H17DDA2F7EC3F4465B5ECC0B10C537262">
          <enum>(1)</enum>
          <header>Establishment</header>
          <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" parent-entity-id="" value="" entity-id="7500">Secretary of Health and Human Services</cato:entity-ref> (in this section referred to as the <quote>Secretary</quote>) shall establish a program of awarding grants to support research on the development and
			 commercialization of applicable tools, treatments, and cures for
			 Alzheimer's disease and other dementias.</text>
				</paragraph>
        <paragraph id="HD86977E07A654D0AB602E208F4CDBB62">
          <enum>(2)</enum>
          <header>Eligible projects</header>
          <text>To be eligible for funding under this section, a project shall—</text>
					<subparagraph id="H142F8B95894D40C19E3A3F25FCE191EA">
            <enum>(A)</enum>
            <text>be designed to further research described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="United States-Israel Alzheimer’s Disease Cooperation Act/s:3/ss:a/p:1" proposed="true">paragraph (1)</cato:entity-ref>; and</text>
					</subparagraph>
          <subparagraph id="HF5BDA2A4B9A0464887F0CB97431B9543">
            <enum>(B)</enum>
            <text>be a joint venture between—</text>
						<clause id="H615A06B0A89B4635A6C6D6C40E271F14">
              <enum>(i)</enum>
							<subclause commented="no" display-inline="yes-display-inline" id="HF8E0BE5379F64BB7A99332D22B63F41E">
                <enum>(I)</enum>
                <text>a for-profit business entity, academic institution, National Laboratory (as defined in <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                    <cato:entity-ref entity-type="act" value="Energy Policy Act of 2005/s:2">section 2 of
			 the Energy Policy Act of 2005</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/42/15801">
                    <cato:entity-ref entity-type="uscode" value="usc/42/15801">42 U.S.C. 15801</cato:entity-ref>
                  </external-xref>)</cato:entity>), or nonprofit entity in
			 the United States; and</text>
							</subclause>
              <subclause id="HAD213D18A29C43DE80C5016282FEBEB3" indent="up1">
                <enum>(II)</enum>
                <text>a for-profit business entity, academic institution, or nonprofit entity in Israel; or</text>
							</subclause>
            </clause>
            <clause id="H1D3EDDC990C349FCBD2F2C55CF5E433F">
              <enum>(ii)</enum>
							<subclause commented="no" display-inline="yes-display-inline" id="HB30D5A12372D47629ED75B0EBB811AE4">
                <enum>(I)</enum>
                <text>the Federal Government; and</text>
							</subclause>
              <subclause id="H6F8458C78EB64C0188D52DCA421B94DD" indent="up1">
                <enum>(II)</enum>
                <text>the Government of Israel.</text>
							</subclause>
            </clause>
          </subparagraph>
        </paragraph>
        <paragraph id="H1BE029B296E74ADEA0E92B393BFAA91D">
          <enum>(3)</enum>
          <header>Applications</header>
          <text>To seek a grant under this section, an applicant shall submit to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> an application in
			 accordance with procedures established by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary,</cato:entity-ref> in consultation
			 with the advisory board established under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="United States-Israel Alzheimer’s Disease Cooperation Act/s:3/ss:a/p:1" proposed="true">paragraph (4)</cato:entity-ref>.</text>
				</paragraph>
        <paragraph id="H792D0E92D3734037BDE0B9223D011443">
          <enum>(4)</enum>
          <header>Advisory board</header>
					<subparagraph id="H7E414001B63748DBAD121B80D42738F6">
            <enum>(A)</enum>
            <header>Establishment</header>
            <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall establish an advisory board—</text>
						<clause id="H99A51878DAB54C4B9B376C5E0A69383A">
              <enum>(i)</enum>
              <text>to monitor the method by which grants are awarded under this section; and</text>
						</clause>
            <clause id="HD620BEC735EF480BB97A3ED4D0EADB5D">
              <enum>(ii)</enum>
              <text>to provide to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> periodic performance reviews of actions taken to carry out this
			 section.</text>
						</clause>
          </subparagraph>
          <subparagraph id="HC32D6B5C0CAA4E349A3B45C95B371AC0">
            <enum>(B)</enum>
            <header>Composition</header>
            <text>The advisory board established under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="United States-Israel Alzheimer’s Disease Cooperation Act/s:3/ss:a/p:4/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> shall be composed of 3 members, to be
			 appointed by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, of whom—</text>
						<clause id="H4E183AA5135945B7A44267EC5FF59AB7">
              <enum>(i)</enum>
              <text>1 shall be a representative of the Federal Government;</text>
						</clause>
            <clause id="H5FCFEC764AFF4C7DBD86DD9CE8C9BDDB">
              <enum>(ii)</enum>
              <text>1 shall be selected from a list of nominees provided by the United States-Israel Binational Science
			 Foundation; and</text>
						</clause>
            <clause id="H42ED7D50A17146B28EC0C8182C29FB30">
              <enum>(iii)</enum>
              <text>1 shall be selected from a list of nominees provided by the United States-Israel Binational
			 Industrial Research and Development Foundation.</text>
						</clause>
          </subparagraph>
        </paragraph>
        <paragraph id="H6A772522A9474C3FB30FF20F18A4EA5F">
          <enum>(5)</enum>
          <header>Contributed funds</header>
          <text>Notwithstanding <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/31/3302">
              <external-xref legal-doc="usc" parsable-cite="usc/31/3302">section 3302</external-xref> of title 31, United States Code</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may accept, retain, and
			 use funds contributed by any person, government entity, or organization
			 for purposes of carrying out this section—</text>
					<subparagraph id="HFE5A474A5DD64D09BCF51D65185B18DC">
            <enum>(A)</enum>
            <text>without further appropriation; and</text>
					</subparagraph>
          <subparagraph id="H4ED8B5234606483BAB17BAD5CFCE5F50">
            <enum>(B)</enum>
            <text>without fiscal year limitation.</text>
					</subparagraph>
        </paragraph>
        <paragraph id="H2EEB1A62F6F3452FAFF2209B21A97E8D">
          <enum>(6)</enum>
          <header>Report</header>
          <text>Not later than 180 days after the date of completion of a project for which a grant is provided
			 under this section, the grant recipient shall submit to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> a
			 report that contains—</text>
					<subparagraph id="H26383A097F1C4A2B9701DB7626B1DF7F">
            <enum>(A)</enum>
            <text>a description of the method by which the recipient used the grant funds; and</text>
					</subparagraph>
          <subparagraph id="H0277F91850C84199B07CC0AB70F9AD17">
            <enum>(B)</enum>
            <text>an evaluation of the level of success of each project funded by the grant.</text>
					</subparagraph>
        </paragraph>
        <paragraph id="HEC32F634FDB4481D82378D0DE98C1885">
          <enum>(7)</enum>
          <header>Classification</header>
          <text>Grants shall be awarded under this section only for projects that are considered to be unclassified
			 by both the United States and Israel.</text>
				</paragraph>
      </subsection>
      <subsection id="HE8F8EE18F0EC4478BF0DDF62E73327FE">
        <enum>(b)</enum>
        <header>Termination</header>
        <text>The grant program and the advisory committee established under this section terminate on the date
			 that is 7 years after the date of enactment of this Act.</text>
			</subsection>
      <subsection id="HF9AF1B03A133409DA66E38A4EC371472">
        <enum>(c)</enum>
        <header>Authorization of appropriations</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="auth-auth-approp">There is authorized to be appropriated <cato:property name="purpose">to carry out <cato:entity-ref entity-type="act" value="United States-Israel Alzheimer’s Disease Cooperation Act/s:3" proposed="true">this section</cato:entity-ref> </cato:property>
            <cato:funds-and-year amount="3000000" year="2015..2021">$3,000,000 for the period of
			 fiscal years 2015 through 2021</cato:funds-and-year>. Any amounts appropriated pursuant to this
			 subsection shall be in addition to amounts accepted, retained, and used
			 pursuant to <cato:entity-ref entity-type="act" value="United States-Israel Alzheimer’s Disease Cooperation Act/s:3/ss:a/p:5" proposed="true">subsection (a)(5)</cato:entity-ref>.</cato:entity>
        </text>
			</subsection>
    </section>
  </legis-body>
</bill>
</doc>